Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study
Publication date
2020-08
Authors
Saberi Hosnijeh, F.
van der Straten, Lina
Kater, Arnon P.
van Oers, Marinus H.J.
Posthuma, Ward F.M.
Chamuleau, Martine E.D.
Bellido, Mar
Doorduijn, Jeanette K.
van Gelder, Michel
Hoogendoorn, Mels
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Keywords
Citation
Hosnijeh, F S, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, Doreen te Raa, G, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, 'Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study', Experimental Hematology, vol. 89, pp. 55-60. https://doi.org/10.1016/j.exphem.2020.08.002